tivantinib + anti-cancer therapy

Tivantinib (ARQ 197) is an oral, selective, small-molecule, non-ATP competitive inhibitor of the c-MET receptor tyrosine kinase, developed by ArQule (a subsidiary of Merck & Co.). The c-MET pathway is frequently dysregulated in human cancers, contributing to tumor cell proliferation, survival, invasion, and angiogenesis. This specific combination therapy regimen involves tivantinib used in conjunction with other anti-cancer agents such as erlotinib, sorafenib, pemetrexed, docetaxel, gemcitabine, irinotecan, or cetuximab. It was primarily investigated for the treatment of advanced refractory solid tumors, including hepatocellular carcinoma (HCC) and non-small cell lung cancer (NSCLC). Despite promising early-phase results, tivantinib failed to meet primary endpoints in several Phase 3 trials, leading to the discontinuation of its development for major indications.

Other names

ARQ-197ARQ197ARQ 197tivantinib combination therapy